The FDA Keeps Flagging Compounded-GLP-1 Sellers for the Same Two Claims. Here's How to Spot Them.

Most FDA news lands on you as a worry. This one is the rare piece that hands you a tool. For the better part of a year, the agency has been reading the marketing copy of compounded-GLP-1 sellers — the telehealth sites, the “get your prescription in ten minutes” storefronts — and mailing warning letters when the copy crosses a line. And here's the useful part: the letters keep flagging the same two claims. Learn to hear those two claims, and you've got a lie detector you can run in the time it takes to skim a homepage.

What the FDA actually did

On March 3, 2026, the FDA announced 30 warning letters to telehealth companies for making “false or misleading claims regarding compounded GLP-1 products” on their websites. FDA Commissioner Marty Makary put it plainly in the announcement: “It's a new era. We are paying close attention to misleading claims being made by telehealth and pharma companies across all media platforms — and taking swift action.”

That wasn't a one-off. The FDA noted in the same release that over the previous six months it had sent thousands of letters telling drug and telehealth firms to pull misleading ads — more, the agency said, than it had sent in the entire preceding decade. Then it kept going: during the week of June 15, the FDA sent another 25 warning letters to telehealth companies over compounded semaglutide, tirzepatide, and (in one case) liraglutide, and it stood up a dedicated page spelling out the compliance pitfalls so nobody could claim they didn't know the rules. Mom translation: the referee stopped issuing occasional fouls and started calling the game.

The two claims the FDA keeps flagging

Read enough of these letters and a pattern jumps out. The FDA says the primary violations were “making claims implying sameness with FDA-approved products and obscuring product sourcing by advertising drug products branded with the telehealth firm's name or trademark without qualification, implying they are the compounder.” In plain English, two tells:

• Tell #1: “It's the same as the brand.” Any copy that nudges you toward believing compounded tirzepatide or semaglutide is the same thing as Zepbound, Mounjaro, Ozempic, or Wegovy — same drug, same FDA blessing, just cheaper. It isn't, and the FDA is treating that implication as misbranding. Compounded medications are not FDA-approved; the brand versions went through a review the compounded ones didn't.
• Tell #2: The house-brand shell game. A site slaps its own logo on the vial and the checkout page so it looks like they make your medication, when a compounding pharmacy you're never introduced to is actually the one mixing it. The FDA's objection is that this hides who's really responsible for what goes in your body.

Notice what these two have in common: both work by blurring a line you have every right to see clearly. One blurs the line between “FDA-approved” and “not.” The other blurs the line between the marketing brand and the pharmacy. The whole con is fog.

Why this is actually good news for you

Here's the thing that made me want to write this up. The FDA didn't just scold some companies — it told you, for free, the two phrases the shakiest operators can't resist using. That's a gift. You don't need a pharmacy background to run this check; you need to know what you're listening for.

And the FDA was refreshingly blunt about the underlying fact this whole site is built on: compounded drugs “are not FDA-approved,” which means “the agency does not review their safety, effectiveness or quality before they are marketed,” and they are “also not the same as generic drugs, which are FDA-approved.” That's not an argument against compounded tirzepatide — plenty of people, me included, use it with a real provider and a real pharmacy. It's an argument for knowing exactly what you're buying and from whom. A company that volunteers that unflattering fact is showing you its cards. A company that papers over it with “same as Ozempic” graphics just failed the test the FDA is now enforcing.

How to spot both in five minutes

Before you give any GLP-1 site your card, run the two tells:

• Hunt for the “sameness” wording. Search the homepage and FAQ for “same as,” “identical to,” “equivalent to,” or a big brand name doing the selling. Honest sellers say “compounded tirzepatide” and state plainly that it isn't FDA-approved. If a site leans on the brand's reputation instead of its own transparency, believe the lean.
• Make them name the pharmacy. Ask — in writing — which licensed compounding pharmacy fills your prescription: name, city, state. If the answer is just the website's own brand, or a shrug, that's the house-brand shell game the FDA is flagging. Then verify that pharmacy's license with your state board or NABP's Safe Pharmacy search.
• Confirm a real intake comes before any money. A licensed provider should review your history first. Card-first is still the single most reliable tell there is.

These slot right into the longer version I keep pointing you to — the questions to ask any telehealth before you sign up live in my provider checklist.

Sources & further reading

• FDA: “FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s” (March 3, 2026) — the 30 warning letters, the Commissioner's statement, the two primary violations, and the “thousands of letters” figure
• FDA: “What to Know When Promoting Compounded Drugs” — the agency's compliance page for telehealth companies, published alongside the June round of letters
• FDA: Concerns with unapproved GLP-1 drugs used for weight loss — including fraudulent products labeled with the names of pharmacies that never made them
• Related: how tirzepatide online scams actually work, what the FDA's 503B bulk proposal means for compounded tirzepatide, and my provider checklist

Medical disclaimer: The Compounded Brief is not a pharmacy, prescriber, or medical provider, and nothing here is medical advice. Compounded medications are not FDA-approved; obtain them only from a licensed compounding pharmacy after evaluation by a licensed provider. Talk to a licensed professional before starting, stopping, or changing any medication.